Gap Inc V.GAP

in the Whitehorse Star....

[piconator2]

PharmaGap Inc. is a bio-pharma company

developing proprietary drug compounds

which target the underlying cell signaling

pathways known to be the root cause of a

range of human diseases, and specically

cancer. -is type of drug therapy focuses on

restoring normal, healthy cell cycles, thereby

slowing growth and killing cancer cells and

the tumors they form. -is approach

contrasts with the primary focus of current

cancer care, which is centered on excision

(where possible) followed by chemotherapy

and radiation therapy – put simply: rst cut,

then poison. One such cell signaling enzyme

is a cellular protein family called Protein

Kinase C (“PKC”). Scientists and medical

researchers from around the world have

demonstrated the strong link between the

PKC family of enzymes and many serious

diseases, including cancer, diabetes and

in ammatory diseases like arthritis.

PharmaGap’s drug compounds are

designed from rst principles to inhibit

abnormal activity of PKC found in human

disease conditions.

PharmaGap’s business model is to

out-license the results of its drug program to

Big Pharma once clinical trials are

commenced, or earlier if a compelling

valuation can be achieved for shareholders.

PharmaGap has completed the discovery

phase of development for GAP-107B8, and

has over the past 12 months worked with

recognized, independent testing

organizations and collaborators to validate

its lead cancer drug GAP-107B8. -ese

organizations included the National Cancer

Institute in Washington, Memorial

Sloan-Keering Cancer Centre in New York,

and the Oawa Hospital Research Institute.

GAP-107B8’s compelling bioactivity,

ecacy and excellent safety prole has been

demonstrated in vitro and in animal models.

Testing performed at the Oawa Hospital

Research Institute (OHRI), the National

Cancer Institute (NCI), and the Memorial

Sloan-Keering Cancer Center have all

demonstrated GAP-107B8’s strong potential

for the growth inhibition and destruction of

a wide spectrum of cancer types. Some of

the most striking results showed a dose

dependent eect of the drug in causing

cancer cell death: Prostate Cancer up to

100%; Melanoma up to 92%; and Colon

Cancer up to 86%.

With this work close to completion, the

Company is now embarking on the

development of the clinical trial program for

GAP-107B8 and generation of data required

for the application to commence clinical

trials, with the objective of commencing

clinical trials in 2012.

Because of the strong support

PharmaGap has received from investors in

this area, company management will be

holding a presentation in Whitehorse on

August 3rd. In aendance will be Bob

McInnis (CEO), Dr. Ken Sokoll (VP

Clinical Development), and Rod Bryden

(Chairman).

Location: Gold Rush Inn – Town Hall Meeting Room

Date: Tuesday, August 3rd

Time: 7:00 – 9:00 PM (Doors open at 6:00 PM)

Whether you are a current shareholder or not we have all been touched by the horrors of cancer in one way or another.

If you would like to know more about the cuing edge research that is ongoing in the

War on Cancer you are more than welcome to aend what will be a very informative presentation.

Robert C. McInnis,

President & Chief Executive Ocer

Bob joined PharmaGap in December 2004. Prior to

this, Bob was the Director of Financial Programs at

World Heart Corporation, dealing with various

nancial structuring programs including

responsibility for U.S. and Canadian capital markets

regulatory aairs. Previously, Bob was president of

SC Stormont Corporation and was involved in the

corporate nancial management for the Oawa

Senators Hockey Club and -e Corel Centre. Before

that, Bob was employed at SHL Systemhouse Inc., at

the time, Canada’s largest computer system

integration company where he held a number of key

nancial management roles including corporate

structuring, and mergers and acquisitions activity.

Bob is a chartered accountant and holds a Bachelor of

Mathematics degree from the University of Waterloo.

Dr. Kenneth K. Sokoll,

PhD, VP Clinical Development

Dr. Sokoll has served in an executive role in the

drug development industry since 2003 and has

served in a variety of product development roles

since 1994 in Canada, the United States and France.

He has assumed full responsibility for clinical trials,

clinical trial protocol development and delivery, as

well as development of strategies for clinical

development of lead drug candidates, preclinical

development, and chemistry, manufacturing and

control requirements, among others.

Roderick M. (Rod) Bryden,

Chairman of the Board

Mr. Bryden is Chairman of PharmaGap and the

founder and Chairman of SC Stormont Inc., a

business advisory company which participates in the

development of small to mid-sized Canadian

businesses. He is also the President of Plasco Energy

Group and a director of Clearford Industries. He was

the former Chairman and CEO of WorldHeart

Corporation, Paperboard Industries, Systemhouse

Ltd. and was the CEO of Terrace Corporation, the

principal owner of the Oawa Senators NHL hockey

franchise. Mr. Bryden has taught law at the

University of Saskatchewan and was a senior federal

government ocial. He has a B.A. (Hon.

Economics) from Mount Allison University (New

Brunswick), LLB from the University of New

Brunswick and LLM from the University of

Michigan, Ann Arbor.